GlassScriptPhysician profile
Amanda Star Saunders
NPI 1689909103
$2,053.69
in general payments reported to CMS, 2019-2025
21 companies · $373 in 2025
The $373 reported for 2025 was more than what 88% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.49 · 2022: $106 · 2023: $1,100 · 2024: $453 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $239.13 | 2023-2025 | Rebinyn, Alhemo |
| Jazz Pharmaceuticals INC. | $224.55 | 2023-2024 | |
| Hema Biologics, LLC | $219.06 | 2022-2023 | Sevenfact |
| Novartis Pharmaceuticals Corporation | $214.59 | 2022-2024 | |
| Chiesi USA, INC. | $195.52 | 2022-2025 | Ferriprox |
| Pfizer INC. | $166.66 | 2023-2025 | |
| Csl Behring | $165.35 | 2023-2025 | Hemgenix, Idelvion |
| Servier Pharmaceuticals LLC | $108.35 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $72.68 | 2023-2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $69.72 | 2022-2025 | Ultomiris, Koselugo |
| Genentech USA, INC. | $56.60 | 2024-2025 | Hemlibra |
| Medunik USA INC. | $54.20 | 2024-2025 | Siklos |
| Janssen Pharmaceuticals, INC | $50.21 | 2024-2025 | Spravato |
| Emmaus Medical, INC. | $48.07 | 2023 | Endari |
| Fennec Pharmaceuticals, INC. | $38.99 | 2023 | Pedmark |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Y-Mabs Therapeutics, INC. | $29.56 | 2024 | Danyelza |
| Sanofi Pasteur INC. | $24.26 | 2024 | |
| Abbvie INC. | $21.49 | 2021 | |
| Rare Disease Therapeutics, INC. | $19.60 | 2025 | Xromi |
| Duchesnay USA Incorporated | $18.08 | 2022 | |
| Uswm, LLC | $17.02 | 2024 | Iwilfin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.